AI-generated analysis. Always verify with the original filing.
Enzon Pharmaceuticals, Inc. entered into the Eighth Amendment to the Section 382 Rights Agreement on February 27, 2026, extending the Final Expiration Date of the rights from noon, New York City time on March 2, 2026, to noon, New York City time on March 11, 2026. The Company also issued a press release announcing an extension of the expiration date for its exchange offer of Series C Preferred Stock for common stock to one minute after 11:59 p.m., Eastern time, on March 9, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On February 27, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Eighth Amendment to the Section
. Item 7.01 Regulation FD Disclosure. On February 27, 2026, the Company issued a press release announcing an extension to the expiration date for the exchange o
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 4.1 Eighth Amendment to the Section 382 Rights Agreement, dated as of February 27, 2026, by
Material Agreement